Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Liabilities and Shareholders Equity (2016 - 2025)

Traws Pharma (TRAW) has disclosed Liabilities and Shareholders Equity for 14 consecutive years, with $10.6 million as the latest value for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 57.47% year-over-year to $10.6 million; the TTM value through Dec 2025 reached $57.7 million, down 18.39%, while the annual FY2025 figure was $10.6 million, 57.47% down from the prior year.
  • Liabilities and Shareholders Equity hit $10.6 million in Q4 2025 for Traws Pharma, down from $12.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $60.0 million in Q3 2021 and bottomed at $8.9 million in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $31.8 million, with a median of $28.8 million recorded in 2023.
  • Year-over-year, Liabilities and Shareholders Equity skyrocketed 177.58% in 2021 and then crashed 66.95% in 2024.
  • Traws Pharma's Liabilities and Shareholders Equity stood at $55.5 million in 2021, then fell by 29.03% to $39.4 million in 2022, then plummeted by 42.39% to $22.7 million in 2023, then rose by 10.05% to $25.0 million in 2024, then crashed by 57.47% to $10.6 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $10.6 million, $12.4 million, and $15.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.